Loading...
Channel Therapeutics Corporation
PTHS•NYSE
Healthcare
Biotechnology
$18.97
$2.50(15.18%)
Channel Therapeutics Corporation (PTHS) Company Profile & Overview
Explore Channel Therapeutics Corporation’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Channel Therapeutics Corporation (PTHS) Company Profile & Overview
Clinical-stage biopharma focused on ZELSUVMI™ (berdazimer) topical gel for molluscum contagiosum, plus NaV1.7 pain pipeline. Resulted from merger of Channel Therapeutics with Ligand’s LNHC/Pelthos.
SectorHealthcare
IndustryBiotechnology
Contact Information
4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703, Durham, NC, 27703
Company Facts
IPO DateJul 2, 2025
CountryUS
Actively Trading